Total submissions: 33
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000111799 | SCV000244845 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-01-12 | reviewed by expert panel | curation | Class 1 not pathogenic based on frequency >1% in an outbred sampleset. Frequency 0.05769 (Asian), derived from 1000 genomes (2012-04-30). |
Labcorp Genetics |
RCV000047360 | SCV000075373 | benign | Hereditary breast ovarian cancer syndrome | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000111799 | SCV000154026 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2014-03-13 | criteria provided, single submitter | literature only | |
Ambry Genetics | RCV000162531 | SCV000212930 | benign | Hereditary cancer-predisposing syndrome | 2014-11-18 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Illumina Laboratory Services, |
RCV000111799 | SCV000403076 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2018-03-06 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000047360 | SCV000494301 | benign | Hereditary breast ovarian cancer syndrome | 2014-02-19 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000474769 | SCV000540973 | benign | Familial cancer of breast | 2017-02-23 | criteria provided, single submitter | clinical testing | |
Cancer Genetics and Genomics Laboratory, |
RCV000496808 | SCV000586864 | benign | not specified | 2017-04-18 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000656647 | SCV000602711 | benign | not provided | 2023-11-07 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000162531 | SCV000682939 | benign | Hereditary cancer-predisposing syndrome | 2015-04-13 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000496808 | SCV000693597 | benign | not specified | 2017-11-01 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000496808 | SCV000806892 | benign | not specified | 2017-06-28 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000496808 | SCV001470156 | benign | not specified | 2020-06-15 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV000656647 | SCV002009475 | benign | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
National Health Laboratory Service, |
RCV000047360 | SCV002026043 | benign | Hereditary breast ovarian cancer syndrome | 2022-04-19 | criteria provided, single submitter | clinical testing | |
Genetics Program, |
RCV000047360 | SCV002515198 | benign | Hereditary breast ovarian cancer syndrome | 2021-11-01 | criteria provided, single submitter | research | |
Sema4, |
RCV000162531 | SCV002537999 | benign | Hereditary cancer-predisposing syndrome | 2021-05-11 | criteria provided, single submitter | curation | |
Center for Genomic Medicine, |
RCV000496808 | SCV002551074 | benign | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV003149698 | SCV003838913 | benign | Breast and/or ovarian cancer | 2021-11-09 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000656647 | SCV004699820 | benign | not provided | 2023-12-01 | criteria provided, single submitter | clinical testing | BRCA1: BP4, BP7, BS1, BS2 |
Breakthrough Genomics, |
RCV000656647 | SCV005251101 | benign | not provided | criteria provided, single submitter | not provided | ||
Breast Cancer Information Core |
RCV000111799 | SCV000144344 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2006-07-19 | no assertion criteria provided | clinical testing | |
Sharing Clinical Reports Project |
RCV000111799 | SCV000189325 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2011-03-03 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV000496808 | SCV000591239 | benign | not specified | no assertion criteria provided | clinical testing | The BRCA1 p.Lys38= variant was identified in 16 of 604 proband chromosomes (frequency: 0.026) from Asian and Colombian individuals or families with hereditary breast and/or ovarian cancer or early-onset breast cancer and was present in 3 of 142 control chromosomes (frequency: 0.021) from healthy individuals (Torres_2007_17080309, Ho_2000_10951344, Chen_2003_12602912, Song_2006_16835750, Toh_2008_18431501). The variant was also identified in dbSNP (ID: rs1800062) as “With Uncertain significance, other allele”, ClinVar and Clinvitae (11x classified as benign by ENIGMA, Laboratory Corporation of America, Baylor Miraca Genetics, British Columbia Cancer Agency (COGR), Sinai Health System (COGR), ARUP Laboratories, Invitae, Counsyl, Ambry Genetics, SCRP, BIC; 2x classified as likely benign by Illumina Clinical Services and CHEO), GeneInsight-COGR (classified as likely benign/benign by COGR consensus and Sinai Health System), LOVD 3.0 (11 entries, classified as does not affect function or not classified), UMD-LSDB (37 entries, 2 of which have co-occurring pathogenic variants), BIC Database (18 entries, classified as not pathogenic), and the Zhejiang Colon Cancer Database (5 entries classified as no known pathogenicity). The variant was not identified in the COSMIC, MutDB, or ARUP Laboratories databases. The variant was identified in control databases in 1135 of 276592 chromosomes (18 homozygous) at a frequency of 0.004 increasing the likelihood this could be a low frequency variant (Genome Aggregation Database Feb 27, 2017). Breakdown of the observations by population include African in 4 of 23984 chromosomes (freq: 0.0002), Other in 13 of 6450 chromosomes (freq: 0.002), Latino in 368 of 34346 chromosomes (freq: 0.01), European Non-Finnish in 2 of 126380 chromosomes (freq: 0.00002), East Asian in 741 of 18846 chromosomes (freq: 0.04), European Finnish in 1 of 25776 chromosomes (freq: 0.00004), and South Asian in 6 of 30688 chromosomes (freq: 0.0002) while the variant was not observed in the Ashkenazi Jewish population. The p.Lys38= variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. The variant occurs outside of the splicing consensus sequence and 2 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing. However, this information is not predictive enough to assume pathogenicity. In summary, based on the above information this variant meets our laboratory's criteria to be classified as benign. | |
Diagnostic Laboratory, |
RCV000111799 | SCV000733682 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion criteria provided | clinical testing | ||
Mayo Clinic Laboratories, |
RCV000656647 | SCV000778780 | benign | not provided | 2016-12-19 | no assertion criteria provided | clinical testing | |
True Health Diagnostics | RCV000162531 | SCV000787892 | likely benign | Hereditary cancer-predisposing syndrome | 2017-09-13 | no assertion criteria provided | clinical testing | |
Brotman Baty Institute, |
RCV000111799 | SCV001241896 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro | ||
Laboratory of Diagnostic Genome Analysis, |
RCV000496808 | SCV001798401 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics Laboratory, |
RCV000496808 | SCV001906278 | benign | not specified | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000656647 | SCV001930570 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000496808 | SCV001954762 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000496808 | SCV001965154 | benign | not specified | no assertion criteria provided | clinical testing |